Medicus Pharma Ltd. (MDCX) Stock Forecast
MDCX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.75 / 5 from 4 analysts
- Price target
- $203.75 average of analyst targets
- Upside to target
- +6,169.2% from the latest close
- Next earnings
- November 13, 2026 EPS estimate $-8.50
- 52-week range
- $3.12 – $135.00
MDCX analyst ratings
4 analystsNumber of analysts at each rating.
MDCX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
MDCX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$6.50 | −$6.50 | −$6.50 | −$54.66 | +88.1% | 1 |
| Current fiscal year (2026) | −$27.00 | −$27.00 | −$27.00 | −$99.97 | +73.0% | 1 |
| Next fiscal year (2027) | −$13.61 | −$25.00 | −$0.83 | −$32.90 | +58.6% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
MDCX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 3 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 4 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 4 |
MDCX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
MDCX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.00 | $0.00 | −$8.50 | −$8.50 | −$6.50 | — | 0 up · 0 down |
| Current fiscal year (2026) | −$60.50 | −$60.50 | −$31.50 | −$31.50 | −$27.00 | −55.4% | 0 up · 0 down |
| Next fiscal year (2027) | −$19.50 | −$18.83 | −$14.67 | −$14.67 | −$13.61 | −30.2% | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
MDCX earnings surprises
Reported EPS vs the consensus estimate for the last 11 quarters; MDCX beat in 1 of 8.
What analysts expect from MDCX
4 analysts cover Medicus Pharma; their consensus rating is strong buy (4.75 on a 1–5 scale, where 5 is a strong buy). The average price target is $203.75, 6,169.2% above the latest close of $3.25. Analysts expect earnings of −$27.00 per share for 2026, +73.0% from a year earlier. For 2027 the average estimate is −$13.61 per share. Medicus Pharma beat the EPS estimate in 1 of the last 8 quarters.
Related: MDCX income statement, MDCX key metrics, MDCX chart. See the MDCX stock overview for the latest quote and news.
MDCX forecast FAQ
What is Medicus Pharma's price target?
The average analyst price target for Medicus Pharma is $203.75, 6,169.2% above the latest close of $3.25.
Is Medicus Pharma a buy, hold or sell?
Of 4 analysts covering Medicus Pharma, 3 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Medicus Pharma's EPS forecast?
Analysts forecast −$27.00 per share for 2026 (range −$27.00 to −$27.00); for 2027 the estimate is −$13.61.
When does Medicus Pharma report earnings?
Medicus Pharma is expected to report results for the quarter ending September 30, 2026 on November 13, 2026; the EPS estimate is $-8.50.
Does Medicus Pharma usually beat earnings estimates?
Medicus Pharma reported EPS at or above the analyst estimate in 1 of the last 8 quarters.